

DAFTAR PUSTAKA

- Ai J, *et al* (2020). Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways" *cancer cell Int*: (19):p. 329. Available from: <https://doi.org/10.1186/s12935-019-1038-0>
- Ali-Eldin ZA, Al Baz HS, Naguib GG, Samy MH. (2024). " Dickkopf-1 (DKK1): A diagnostic marker for hepatocellular carcinoma (HCC) on top of chronic hepatitis C virus related diseases <https://doi.org/10.1093/qjmed/hcad069.454>
- Borgia, M. *et al.* (2021) "Role of virus-related chronic inflammation and mechanisms of cancer immune-suppression in pathogenesis and progression of hepatocellular carcinoma." doi:10.3390/cancers.
- Budihusodo, U. (2014) *Karsinoma hati. buku ajar ilmu penyakit dalam*. VI.edited interna publishing pusat penerbitan Ilmu Penyakit Dalam jl. diponegoro 71 jakarta pusat 10430.
- Cassinotto, C., Aubé, C. and Dohan, A. (2017) "Diagnosis of hepatocellular carcinoma: An update on international guidelines," *diagnostic and interventional imaging*. Elsevier Masson SAS, pp. 379–391. doi:10.1016/j.diii.2017.01.014.
- Chaiteerakij, R., Addissie, B.D. and Roberts, L.R. (2018) "Update on biomarkers of hepatocellular carcinoma," *clinical gastroenterology and hepatology*. W.B. Saunders, pp. 237–245. doi:10.1016/j.cgh.2013.10.038.
- Chu, Hang Yin, *et al.* (2021) "Dickkopf-1: a promising target for cancer immunotherapy." *frontiers in immunology*. (12):p.658-97.
- Desai, A. *et al.* (2019) "Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review," *world journal of hepatology*. baishideng publishing group co, pp. 1–18. doi:10.4254/wjh.v11.i1.1.
- Dimitroulis, D. *et al.* (2017) "From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world," *world journal of gastroenterology*. baishideng publishing group co, pp. 5282–5294. doi:10.3748/wjg.v23.i29.5282.
- Dinda Aprilistya Puri, Murti, S. and Riastiti, Y. (2021) "Insidensi dan karakteristik karsinoma hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda," *jurnal sains dan kesehatan*, 3(2), pp. 158–164. doi:10.25026/jsk.v3i2.275.
- Fadillah D, (2017) *Insidensi penyakit kanker/mekanisme kanker Di RSUP. Dr. Wahidin Sudirohusodo Makassar Periode Januari 2015 - Juni 2017*, scribd.



2022). "DKK1 promotes hepatocellular carcinoma inflammation, invasion: Implication of TGF- β 1" *PLOS ONE*: available from: [/10.1371/journal.pone.0223252](https://doi.org/10.1371/journal.pone.0223252)

(2018) "EASL Clinical practice guidelines: management of hepatocellular carcinoma," *Journal of Hepatology*, 69(1), pp. 182–236. doi:10.1016/j.jhep.2018.03.019.

- Gao TM, *et al.* (2024) "Novel preoperative type iv collagen to predict the risk of hepatocellular carcinoma in patients with hepatitis b virus-related cirrhotic portal hypertension after laparoscopic splenectomy and azygoportal disconnection" *Journal of Hepatocellular Carcinoma*: (11) :p. 2411–2420. available from: doi.org/10.2147/JHC.S425814
- Giralt,I,Gallo-Oller,G,Navarro,N.*et al* (2021). Dickkopf proteins and their role in cancer: a family of wnt antagonists with a dual role. *pharmaceuticals* 14, 810.<https://doi.org/10.3390/ph14080810>.
- Ghouri, Y.A., Mian, I. and Rowe, J.H. (2017) "Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis," *Journal of Carcinogenesis*.Medknow publications, pp. 1–8. available from: doi:10.4103/jcar.JCar_9_16.
- Globocan. (2022). "World [Internet]". [cited 2024 Apr 5]. available from: <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>
- Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, *et al.* (2024). "Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update." *J Clin Oncol*. 2024;00:p. 1-21.
- Guyton AC, H.J. (2016) Buku ajar fisiologi kedokteran. 12th edn. Jakarta: EGC.
- Hennedige, T. and Venkatesh, S.K. (2016) "Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring," *Cancer Imaging*, pp. 530–547. doi:10.1102/1470-7330.2012.0044.
- Ibraheem, M.R. and Elmogy,M.(2016) "Automated segmentation and classification of hepatocellular carcinoma using fuzzy c-means and SVM," in *Studies in Computational Intelligence*. springer verlag, pp. 193–210. doi:10.1007/978-3-319-33793-7_9.
- Jeng J, *et al* (2020). "Serum dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma". *chin clin oncol*; (1):p.4. available from:<https://doi.10.3978/j.issn.2304-3865.2012.08.03>
- Kikuchi A, *et al.* (2021) Dickkopf signaling,beyond wnt mediated biology <https://doi.org/10.1016/j.semcd.2021.11.003>
- Kim,S,U, *et al* (2024). "Serum dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma". *YMJ*; 56(5):p. 1296-1306. available from: <http://dx.doi.org/10.3349/ymj.2015.56.5.1296>



onsensus nasional penatalaksanaan karsinoma sel hati,edited by diterbitkan oleh Perhimpunan Peneliti Hati Indonesia.

et al. (2022). "Alpha-fetoprotein binding mucin and scavenger available bio-target for treating cancer" *front. oncol.*(11):625936. doi:10.3389/fonc.2021.625936

- Li, S. *et al.* (2020) "Risk factors, pathogenesis, and strategies for hepatocellular carcinoma prevention: emphasis on secondary prevention and its translational challenges," *Journal of Clinical Medicine*. MDPI, pp. 1–31. doi:10.3390/jcm9123817.
- Llovet, J.M. *et al.* (2021) "Hepatocellular carcinoma, <https://doi.org/10.1038/s41572-020-00240-3>
- Liyuan Hao *et al* (2023) The current status and future of PD-L1 in liver cancer DOI: 10.3389/fimmu.2023.1323581
- Maulina, M. (2018). Histopatologi hepar. Lhokseumawe.
- Nursriyanti, D, *et al* (2023) "Analysis of alpha-fetoprotein as a staging determiner of hepatocellular carcinoma progresivity". *IJCP*. Vol. 29(3). pp. 268-271. available at: <https://www.indonesianjournalofclinicalpathology.org>
- Olbrich A,*et al* (2022). "Dickkopf- related protein 1 as response marker for transarterial chemoembolization of hepatocellular carcinomas". *cancers*: (14);p.4807. available from: <https://doi.org/10.3390/cancers14194807>
- Ozougwu, J.C. (2017) Physiology of the Liver. *International Journal of Research in Pharmacy and Biosciences*, 4, 13-24.
- Paraskevi. A Farazi (2020) Hepatocellular carcinoma pathogenesis: from genes to environment doi:10.1038/nrc1934
- Paulsen F, J.W. (2018) Buku ajar anatomi sobotta. edited elsevier.
- Pangribowo S (2019), (PDF) infodatin beban kanker di indonesia 2019 pusat data dan informasi Kementerian Kesehatan RI https://www.academia.edu/108539942/Infodatin_Kanker_2019
- Shen Q, *et al.* (2022) "Serum dkk1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study" *lancet oncol*. 13(8):817–826. doi:10.1016/S1470-2045(12)70233-4
- Spear, B.T. (2017) "Alpha-fetoprotein,"<https://doi.org/10.1016/B978-0-12-374984-0.00039-5>
- Solhi, R., Pourhamzeh, M.*et al* (2024). Novel biomarkers for monitoring and management of hepatocellular carcinoma. *Cancer Cell International*, 24(1),428 <https://doi.org/10.1186/s12935-024-03600-1>
- Subramaniam, S., Kelley, R.K. and Venook, A.P. (2018) "A review of hepatocellular carcinoma (HCC) staging systems," *chinese clinical oncology*. AME publishing company. doi:10.3978/j.issn.2304- 3865.2013.07.05.



"Dickkopf-1 promotes angiogenesis and is a biomarker for hepatic hepatocellular carcinoma" *Int. J. Mol. Sci*: (23):p. 2801. available doi.org/10.3390/ijms23052801

'Global cancer statistics 2020: globocan estimates of incidence and worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 70(3), pp. 209–249. available at: <https://doi.org/10.3322/caac.21660>.

- Trevisani, F, D'Intino, *et al* (2020). Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. *Journal of Hepatology*, 34(4), 570–575. doi: 10.1016/s0168-8278(00)00053-2.
- Tung EK, Mak CK, Fatima S, *et al.* (2022) “Clinicopathological and prognostic significance of serum and tissue dickkopf-1 levels in human hepatocellular carcinoma” <https://doi.org/10.1111/j.1478-3231.2011.02597.x>
- Wang, X. and Wang, Q. (2018) “Alpha-fetoprotein and hepatocellular carcinoma immunity,” *Canadian Journal of Gastroenterology and Hepatology*. Hindawi Limited. doi:10.1155/2018/9049252.
- Watany M, *et al* (2023). "Study of dickkopf-1 (DKK 1) gene expression in hepatocellular carcinoma patients". *Journal of Clinical and Diagnostic Research*: 11(2):p.OC32-OC34. Available from: <https://10.7860/JCDR/2017/23095.9450>
- Yang, J.D. *et al.* (2019) “A global view of hepatocellular carcinoma: trends, risk, prevention and management,” *nature reviews gastroenterology and hepatology*. Nature Publishing Group, pp. 589–604. doi:10.1038/s41575- 019-0186-y.
- Yu, S.J. (2016) “A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016,” *clinical and molecular hepatology*, pp. 7–17. doi:10.3350/cmh.2016.22.1.7.
- Zekri AR, *et al.* (2020). "The possible role of dickkopf-1, golgi protein- 73 and midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study". *Scientific Reports*:(10):p.5156. available from: <https://doi.org/10.1038/s41598-020-62051-6>
- Zhao, y-j, *et al* (2017). *Tumor markers for hepatocellular carcinoma. molecular and clinical oncology*, 1(4), 593–598. doi:10.3892/mco.2013.119
- Zhu, Guohua, *et al.* (2021) "Expression and role of dickkopf-1 (dkk1) in tumors: from the cells to the patients doi: [10.2147/CMAR.S275172](https://doi.org/10.2147/CMAR.S275172)."
- Zhu, K., Dai, Z. & Zhou, J (2013) Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. *Biomark Res* 1, 10 (2013). <https://doi.org/10.1186/2050-7771-1-10>

